In the final model adjusting for sex, age, history of type 2 diabetes, hypertension gout, and urolithiasis at baseline, time-update absolute CD4 cell count <200 cells/mm3, availability of previous serum creatinine measurement and propensity score stratification, and compared to AZT + 3TC + NVP, the following three regimens were associated with a higher risk of CKD: TDF + 3TC + LPV/r (aSHR 6.5, 95% CI 3.9–11.1), TDF + 3TC + NVP (aSHR 3.8, 95% CI 2.3–6.0), and TDF + 3TC/FTC + EFV (aSHR 1.6, 95% CI 1.2–2.3) (Table 3). The gene discussed is CD4; the disease is type 2 diabetes mellitus.